Liver Failure & Liver Disease
Article first published online: 5 JAN 2004
Published 2004 American Association for the Study of Liver Diseases
Volume 39, Issue 1, pages 188–196, January 2004
How to Cite
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., Liang, T. J., Yanovski, J. A., Kleiner, D. E. and Hoofnagle, J. H. (2004), A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 39: 188–196. doi: 10.1002/hep.20012
This is a US goverment work. There are no restrictions on its use.
The authors are employees of the US government and have not received salary, honoraria, grant funds, or support from the companies that produce pioglitazone or any other thiazolidinedione.
- Issue published online: 5 JAN 2004
- Article first published online: 5 JAN 2004
- Manuscript Accepted: 8 OCT 2003
- Manuscript Received: 29 AUG 2003
- National Center for Minority Health and Health Disparities. Grant Number: Z01-HD-00641
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance plays a central role. This prospective study evaluates the role of insulin-sensitizing agent in treatment of NASH. Eighteen nondiabetic patients with biopsy-proven NASH were treated with pioglitazone (30 mg daily) for 48 weeks. Tests of insulin sensitivity and body composition as well as liver biopsies were performed before and at the end of treatment. By 48 weeks, serum alanine aminotransferase values fell to normal in 72% of patients. Hepatic fat content and size as determined by magnetic resonance imaging decreased, and glucose and free fatty acid sensitivity to insulin were uniformly improved. Histological features of steatosis, cellular injury, parenchymal inflammation, Mallory bodies, and fibrosis were significantly improved from baseline (all P < 0.05). Using strict criteria, histological improvement occurred in two-thirds of patients. Pioglitazone was well tolerated; the main side effects were weight gain (averaging 4%) and an increase in total body adiposity. In conclusion, these results indicate that treatment with an insulin-sensitizing agent can lead to improvement in biochemical and histological features of NASH and support the role of insulin resistance in the pathogenesis of this disease. The long-term safety and benefits of pioglitazone require further study. (HEPATOLOGY 2004;39:188–196.)